bevacizumab,panitumumab
amgen,roche,takeda
['crcsm', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'rectal', 'paradigm', 'colorectal', 'beva']
#asco2022 the story is closed ? in left sided colorectal tumors anti-egfr plus doublet chemotherapy (folfox) is superior for os (median 37.9 months) vs beva plus chemo results of phase3 paradigm trial #crcsm 